40
Participants
Start Date
October 4, 2021
Primary Completion Date
December 10, 2021
Study Completion Date
December 10, 2021
Evobrutinib
Participants will receive evobrutinib film-coated tablet, twice daily under fed conditions from Days 4 to 12 in Part 1 and from Days 2 to 8 in Part 2 of the study.
Digoxin
Participants will receive digoxin tablet under fed conditions, once a day on Day 1 and Day 10 in Part 1.
Metformin
Participants will receive metformin oral solution under fed conditions, once a day on Day 1 and Day 10 in Part 1.
Rosuvastatin
Participants will receive rosuvastatin tablet under fed conditions, once a day on Day 1 and Day 10 in Part 1.
Sumatriptan
Participants will receive sumatriptan tablet under fed conditions, once a day on Day 1 and Day 8 in Part 2.
Nuvisan GmbH, Neu-Ulm
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
INDUSTRY